Sign In
Buy LLY
$1,185.71
-6.23 (-0.523%)
At Close: Aug 07, 2026
The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?
06:50am, Friday, 10'th Nov 2023
There's now more than one medicine on the market to treat Alzheimer's disease. Safety and efficacy will be the two major areas of future competition.
Will Eli Lilly's Zepbound be the next big weight-loss drug?
06:30am, Friday, 10'th Nov 2023
Eli Lilly & Co. NYSE: LLY reversed lower on November 9. This came after LLY stock advanced 3.20% after the company got regulators' OK for its weight-loss drug Zepbound.
British regulator confirms review of new pen for Lilly's Mounjaro drug
06:03am, Friday, 10'th Nov 2023
Britain's drug regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), on Friday confirmed that it is reviewing a new injection pen that Eli Lilly plans to use for the U.S. drugmake
Look Out, Ozempic and Wegovy: Eli Lilly Has a New Weight-Loss Drug in Town
05:49am, Friday, 10'th Nov 2023
Eli Lilly just won FDA approval for Zepbound (tirzepatide) as a chronic weight management treatment. Zepbound should generate huge sales over the coming years.
Eli Lilly Was Hoping for 5 Big Drug Launches This Year. Here's How It Has Done Thus Far.
05:40am, Friday, 10'th Nov 2023
Eli Lilly set some ambitious goals for 2023, highlighting a promising mix of assets in its portfolio. The company has obtained multiple drug approvals this year.
Eli Lilly CEO: We know there's high demand for weight-loss drugs and we're ready to meet it
05:17pm, Thursday, 09'th Nov 2023
David Ricks, Eli Lilly CEO, joins 'Closing Bell Overtime' to talk the FDA's approval of its new weight-loss drug, keeping up with demand for the drug, competition in the space and more.
Former FDA commissioner: Expect more competition in Eli Lilly and Novo Nordisk's weight-loss drugs
03:21pm, Thursday, 09'th Nov 2023
Former FDA commissioner Dr. Scott Gottlieb joins 'Power Lunch' to discuss Eli Lilly's highly anticipated weight-loss drug Zepbound, the demand and supply equation in the weight-loss drug space, and mo
Lilly Takes First Jab in Obesity Drug Showdown
02:09pm, Thursday, 09'th Nov 2023
Eli Lilly says its obesity drug's list price is about 20% lower than Novo's Wegovy.
Eli Lilly's Big Win In The Obesity Space Just Got Bigger
01:43pm, Thursday, 09'th Nov 2023
Eli Lilly received FDA approval to sell tirzepatide for obesity treatment, expanding its market beyond diabetes. Shares of Eli Lilly jumped 3.2% on the news, resulting in a $17.3 billion increase in s
Eli Lilly Has Yet Another Ozempic Killer in the Works. Is It a Screaming Buy?
09:35am, Thursday, 09'th Nov 2023
Eli Lilly is eager to steal market share from Novo Nordisk's drug Ozempic. Creating medicines that don't have certain side effects is one strategy.
Eli Lilly: still seeking UK approval on pen for weight-loss drug
08:38am, Thursday, 09'th Nov 2023
Eli Lilly on Thursday said it has not yet gained approval in Britain for the injection pen it plans to use for its Mounjaro drug against obesity and diabetes, adding to uncertainty over timing of the
'Wonder' diabetes drug Mounjaro approved in the UK
07:48am, Thursday, 09'th Nov 2023
Diabetes blockbuster Mounjaro has been approved for use by the UK drugs agency MHRA after two clinical trials showed patients taking shed between 16%-22% of their weight in little more than a year. De
Earnings Estimates Come Under Pressure
07:32pm, Wednesday, 08'th Nov 2023
While Q3 results have been better than expected, there is a notable acceleration in negative estimate revisions over the last few weeks, contrasting the largely favorable revisions trend of the preced
Earnings Estimates Come Under Pressure
07:32pm, Wednesday, 08'th Nov 2023
While Q3 results have been better than expected, there is a notable acceleration in negative estimate revisions over the last few weeks, contrasting the largely favorable revisions trend of the preced
BofA'S Meacham on what's next for Eli Lilly after FDA approves obesity drug
06:33pm, Wednesday, 08'th Nov 2023
Geoff Meacham, Bank of America, joins 'Fast Money' to talk the FDA's approval of Eli Lilly's obesity drug.
